B-cell Lymphoid Proliferations and Lymphomas
Understanding the underlying mechanisms and heterogeneity of B-cell lymphoid proliferations and lymphomas is essential for the development of effective therapies. Our company, renowned for its expertise in biological solutions, is at the forefront of B-cell lymphoid proliferation and lymphoma drug and therapy development services.
Overview of B-cell Lymphoid Proliferations and Lymphomas
B-cell lymphoid proliferations and lymphomas encompass a group of malignancies that arise from B lymphocytes, a crucial component of the immune system. In recent years, extensive research has identified a multitude of targets for therapy development in B-cell lymphoid proliferations and lymphomas. CD20 antigen is one of the targets of this type of disease. Additionally, novel targets, including B-cell receptor (BCR) signaling pathways, Bcl-2 family members, and DNA damage response pathways, have emerged as potential avenues for therapeutic intervention.
Fig.1 Relationship between different definitions of splenic B-cell lymphoma entities. (Alaggio, Rita, et al., 2022)Classification of B-cell Lymphoid Proliferations and Lymphomas
| Tumor-like lesions with B-cell predominance | ||
|---|---|---|
| Precursor B-cell neoplasms | ||
| B-lymphoblastic leukaemias/lymphomas | ||
| with iAMP21 | with high hyperdiploidy | with hypodiploidy |
| with ETV6::RUNX1-like features | with BCR::ABL1 fusion | with ETV6::RUNX1 fusion |
| with TCF3::PBX1 fusion | with IGH::IL3 fusion | with TCF3::HLF fusion |
| with other defined genetic alterations | with BCR::ABL1-like features | with KMT2A rearrangement |
| Mature B-cell neoplasms | ||
| pre-neoplastic and neoplastic small lymphocytic proliferations | ||
| monoclonal B-cell lymphocytosis | chronic lymphocytic leukemia / small lymphocytic lymphoma | |
| splenic B-cell lymphomas and leukaemias | ||
| hairy cell leukemia | splenic marginal zone lymphoma | splenic diffuse red pulp small B-cell lymphoma |
| splenic B-cell lymphoma/leukemia with prominent nucleoli | ||
| lymphoplasmacytic lymphoma | ||
| marginal zone lymphoma | ||
| pediatric nodal marginal zone lymphoma | primary cutaneous marginal zone lymphoma | nodal marginal zone lymphoma |
| extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue | ||
| follicular lymphoma | ||
| cutaneous follicle center lymphoma | ||
| mantle cell lymphoma | ||
| transformations of indolent B-cell lymphomas | ||
| large B-cell lymphomas | ||
| diffuse large B-cell lymphoma, NOS | grey zone lymphoma | |
| Burkitt lymphoma | ||
| KSHV/HHV8-associated B-cell lymphoid proliferations and lymphomas | ||
| lymphoid proliferations and lymphomas associated with immune deficiency and dysregulation | ||
| Hodgkin's lymphoma | ||
| classic Hodgkin lymphoma | nodular lymphocyte predominant Hodgkin lymphoma | |
| Plasma cell neoplasms and other diseases with paraproteins | ||
| monoclonal gammopathies | ||
| diseases with monoclonal immunoglobulin deposition | ||
| heavy chain diseases | ||
| plasma cell myeloma / multiple myeloma | ||
Therapy Development of B-cell Lymphoid Proliferations and Lymphomas
Chemotherapy
Chemotherapy has been a mainstay in B-cell lymphoid proliferations and lymphomas, particularly in aggressive subtypes. Combination regimens, such as CHOP (cyclophosphamide, vincristine, doxorubicin, and prednisone), have shown significant efficacy. However, the development of resistance and associated toxicities necessitates the exploration of alternative therapy options.
Immunotherapy
Immunotherapeutic approaches, including monoclonal antibodies and immune checkpoint inhibitors, have demonstrated remarkable success in B-cell lymphoid proliferations and lymphomas. These therapies harness the power of the immune system to target cancer cells specifically, while sparing normal cells.
Targeted Therapy
Targeted therapies that specifically inhibit abnormal signaling pathways implicated in B-cell lymphoid proliferations and lymphomas have emerged as a significant development in the field. Small molecule inhibitors, such as ibrutinib and idelalisib, have shown impressive efficacy in certain subtypes of B-cell Lymphoid Proliferations and Lymphomas by blocking key signaling molecules.
Our Services
Identification of reliable biomarkers is critical for accurate diagnostics and therapeutic development of B-cell lymphocyte proliferation and lymphoma. Our company utilizes cutting-edge technologies and analytical platforms to discover and validate biomarkers associated with disease progression. In addition, with our diverse therapy development platform, we are committed to driving the development of innovative B-cell lymphocyte proliferation and lymphoma therapies.
Our Therapy Development Platforms
Our company specializes in developing relevant and reliable animal models that recapitulate the complexities of B-cell lymphoid proliferations and lymphomas. In addition to these models, we also offer different animal species for evaluating drug efficacy, safety, and pharmacokinetics to enable informed decision-making during drug development. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
References
- Alaggio, Rita, et al. "The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms." Leukemia 36.7 (2022): 1720-1748.
- Chadburn, Amy, Annunziata Gloghini, and Antonino Carbone. "Classification of B-Cell Lymphomas and Immunodeficiency-Related Lymphoproliferations: What's New?." Hemato 4.1 (2023): 26-41.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.